drugset / Trial / NCT02045732
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
RandomizedSingle-groupDouble-blindTreatment
Summary
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-10
- Completion
- 2015-10
Outcome
Outcome not reported
Stopped: “This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06342674 | Unknown | 0.25 mg/kg | Subcutaneous |
| Subject | PF-06342674 | Unknown | 1.5 mg/kg | Subcutaneous |
| Subject | PF-06342674 | Unknown | 6 mg/kg | Subcutaneous |